HemoGenyx
London
About HemoGenyx
HemoGenyx LLC, a privately held biopharmaceutical company, is developing a revolutionary new treatment for blood diseases, such as leukemia and lymphoma. They leverage a special class of cells, which can generate cancer-free blood stem cells. Their therapy will dramatically increase the efficacy of bone marrow transplants and eliminate the need for donors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $76.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: lse:HEMO
- Website: hemogenyx.com
- Phone: +1 (347) 735-8380
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/hemogenyx-64626 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.